Category Archives: Biotechnology

Sept. 25, 2020 11:00 UTC

LEXINGTON, Mass.--(BUSINESS WIRE)-- Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, announced today the appointment of Julie Hambleton, M.D., to its board of directors. Dr. Hambleton brings extensive clinical oncology drug development and regulatory expertise gained in leadership roles within both the biotechnology and pharmaceutical industries.

We are delighted to welcome Julie to the Accent Board of Directors, said Shakti Narayan, Ph.D., J.D., Chief Executive Officer of Accent. Her insight and experience will be invaluable as we continue to advance our pipeline of novel therapies targeting RNA-modifying proteins.

Accent is developing an exciting pipeline of targeted therapies in this novel area of biology, said Dr. Hambleton. Im thrilled to be working with the board of directors and the Accent team to deliver life-changing therapies to patients.

Dr. Hambleton is a senior biotechnology executive with more than 20 years of experience in clinical drug development from pre-clinical through Phase 4 and post-marketing studies. She has extensive experience working with regulatory agencies, including the U.S. FDA and the European Medicines Agency (EMA), and in filings of Investigational New Drug Applications (INDs), Biologics License Applications (BLAs) and Special Protocol Assessments (SPAs). Dr. Hambleton currently serves as interim Chief Executive Officer at Arch Oncology. Previously, she served as Senior Vice President, Chief Medical Officer and Head of Development at IDEAYA Biosciences, an oncology medicine company, until April 2020. Prior to her role at IDEAYA, she held the positions of Vice President, Head of U.S. Medical at Bristol-Myers Squibb, where she oversaw Medical & Health Economic and Outcomes Research activities in support of the Oncology, Immuno-Oncology, Specialty and Cardiovascular marketed portfolios; Executive Vice President and Chief Medical Officer at Five Prime Therapeutics; and Vice President, Clinical Development, at Clovis Oncology.

Dr. Hambleton began her industry career at Genentech, most recently as Group Medical Director, Global Clinical Development, leading a cross-functional group conducting Phase 2 and 3 trials of Avastin. She also serves on the boards of directors of IGM Biosciences, Inc. and SpringWorks Therapeutics, Inc., both publicly traded biotechnology companies, as well as Arch Oncology, a privately-held biotechnology company. Dr. Hambleton completed her medical and hematology-oncology training at the University of California, San Francisco, where she then served on faculty from 1993 to 2003. She received a B.S. from Duke University, and her M.D. from Case Western Reserve University School of Medicine and was Board-certified in Hematology and Internal Medicine.

About Accent Therapeutics

Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of RNA modification. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth and differentiation. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision therapies, the Company aims to translate extraordinary science into life-changing therapies for patients. For more information, please visit http://www.accenttx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200925005036/en/

See the rest here:
Accent Therapeutics Appoints Oncology Drug Development Veteran Julie Hambleton to its Board of Directors - BioSpace

Dataintelo, one of the worlds leading market research firms has rolled out a new report on Blue Biotechnology market. The report is integrated with crucial insights on the market which will support the clients to make the right business decisions. This research will help both existing and new aspirants for Global Blue Biotechnology Market to figure out and study market needs, market size, and competition. The report provides information about the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities, and the threats faced by key players.

The report also includes the impact of the ongoing global crisis i.e. COVID-19 on the Blue Biotechnology market and what the future holds for it. The pandemic of Coronavirus (COVID-19) has landed a major blow to every aspect of life globally. This has lead to various changes in market conditions. The swiftly transforming market scenario and initial and future assessment of the impact are covered in the report.

Request a sample Report of Blue Biotechnology Market: https://dataintelo.com/request-sample/?reportId=73067

The report is fabricated by tracking the market performance since 2015 and is one of the most detailed reports. It also covers data varying according to region and country. The insights in the report are easy to understand and include pictorial representations. These insights are also applicable in real-time scenarios. Components such as market drivers, restraints, challenges, and opportunities for Blue Biotechnology are explained in detail. Since the research team is tracking the data for the market from 2015, therefore any additional data requirement can be easily fulfilled.

The scope of the report has a wide spectrum extending from market scenarios to comparative pricing between major players, cost, and profit of the specified market regions. The numerical data is supported by statistical tools such as SWOT analysis, BCG matrix, SCOT analysis, and PESTLE analysis. The statistics are depicted in a graphical format for a clear picture of facts and figures.

The generated report is strongly based on primary research, interviews with top executives, news sources, and information insiders. Secondary research techniques are utilized for better understanding and clarity for data analysis.

The Blue Biotechnology Market is divided into the following segments to have a better understanding:

By Application:

Bio-EngineeringGenomicsVaccine DevelopmentDrug DiscoveryOthers

By Type:

EnzymesPharma ProductsBulk ChemicalsBiopolymers

By Geographical Regions:

Ask for Discount on Blue Biotechnology Market Report at: https://dataintelo.com/ask-for-discount/?reportId=73067

The Blue Biotechnology Market industry Analysis and Forecast 20192026 help clients with customized and syndicated reports holding key importance for professionals requiring data and market analytics. The report also calls for market-driven results providing feasibility studies for client requirements. Dataintelo promises qualified and verifiable aspects of market data operating in the real-time scenario. The analytical studies are carried out ensuring client requirements with a thorough understanding of market capacities in the real-time scenario.

Some of the prominent companies that are covered in this report:

Key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report. Following is the list of key players:

Aker BioMarineMarinovaNew England BiolabsPML ApplicationsSea Run HoldingsPICESDonald Danforth Plant Science CenterShell Marine ProductsGeoMarine BiotechnologiesGlycoMarCellgen BiologicalsNurture Aqua TechnologySamudra BiopharmaSanosil Biotech

*Note: Additional companies can be included on request

Reasons you should buy this report:

Dataintelo provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Customized Report and Inquiry for the Blue Biotechnology Market Report: https://dataintelo.com/enquiry-before-buying/?reportId=73067

About US:

DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry.

Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact US:

Name: Alex MathewsPhone No.: +1 909 545 6473Email: [emailprotected] Website: https://dataintelo.com Address: 500 East E Street, Ontario, CA 91764, United States.

Continue reading here:
Blue Biotechnology Market 2019 | Analyzing The Impact Followed By Restraints, Opportunities And Projected Developments | DataIntelo - The Market...

The 47 rating InvestorsObserver gives to Five Prime Therapeutics Inc (FPRX) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 53 percent of stocks in the Biotechnology industry, FPRXs 47 overall rating means the stock scores better than 47 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Five Prime Therapeutics Inc (FPRX) stock is down -0.26% while the S&P 500 has risen 0.11% as of 10:56 AM on Tuesday, Sep 22. FPRX has fallen -$0.01 from the previous closing price of $3.83 on volume of 285,320 shares. Over the past year the S&P 500 is higher by 9.79% while FPRX has fallen -27.51%. FPRX lost -$2.97 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Five Prime Therapeutics Inc (FPRX) Stock.

View post:
Is Five Prime Therapeutics Inc (FPRX) the Top Pick in the Biotechnology Industry? - InvestorsObserver

A detailed research study on the Biotechnology Reagents Market was recently published by DataIntelo. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The report puts together a concise analysis of the growth factors influencing the current business scenario across various regions. Significant information pertaining to the industry analysis size, share, application, and statistics are summed in the report in order to present an ensemble prediction. Additionally, this report encompasses an accurate competitive analysis of major market players and their strategies during the projection timeline.

The latest report on the Biotechnology Reagents Market consists of an analysis of this industry and its segments. As per the report, the market is estimated to gain significant returns and register substantial y-o-y growth during the forecast period.

Request a Sample Report of Biotechnology Reagents Market at: https://dataintelo.com/request-sample/?reportId=79021

According to the report, the study offers details regarding the valuable estimations of the market such as market size, sales capacity, and profit projections. The report documents factors such as drivers, restraints, and opportunities that impacts the remuneration of this market.

An Outline of the Major Key Points of the Biotechnology Reagents Market Report:

Ask for Discount on Biotechnology Reagents Market Report at: https://dataintelo.com/ask-for-discount/?reportId=79021

The Geographical Landscape of the Market Include:

Buy Your Exclusive PDF Copy Now @ https://dataintelo.com/checkout/?reportId=79021

Some of the Major Highlights of TOC Covers:Chapter 1: Executive Summary

Chapter 2: Methodology & Scope

Chapter 3: Market Insights

Chapter 4: Company Profiles

For More Information on this report, Request Inquiry At: https://dataintelo.com/enquiry-before-buying/?reportId=79021

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://dataintelo.com

Here is the original post:
Biotechnology Reagents Market Analyzes The Impact Followed By Restraints And Opportunities And Projected Developments (2020-2027)| Agilent...

Even when a business is losing money, its possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.

So should G&E Herbal Biotechnology (GTSM:4911) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. The first step is to compare its cash burn with its cash reserves, to give us its cash runway.

Check out our latest analysis for G&E Herbal Biotechnology

You can calculate a companys cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. As at June 2020, G&E Herbal Biotechnology had cash of NT$122m and no debt. Looking at the last year, the company burnt through NT$12m. That means it had a cash runway of about 9.8 years as of June 2020. Even though this is but one measure of the companys cash burn, the thought of such a long cash runway warms our bellies in a comforting way. The image below shows how its cash balance has been changing over the last few years.

Whilst its great to see that G&E Herbal Biotechnology has already begun generating revenue from operations, last year it only produced NT$19m, so we dont think it is generating significant revenue, at this point. As a result, we think its a bit early to focus on the revenue growth, so well limit ourselves to looking at how the cash burn is changing over time. Notably, its cash burn was actually down by 63% in the last year, which is a real positive in terms of resilience, but uninspiring when it comes to investment for growth. G&E Herbal Biotechnology makes us a little nervous due to its lack of substantial operating revenue. We prefer most of the stocks on this list of stocks that analysts expect to grow.

Theres no doubt G&E Herbal Biotechnologys rapidly reducing cash burn brings comfort, but even if its only hypothetical, its always worth asking how easily it could raise more money to fund further growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Many companies end up issuing new shares to fund future growth. By looking at a companys cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another years cash burn.

G&E Herbal Biotechnology has a market capitalisation of NT$2.2b and burnt through NT$12m last year, which is 0.6% of the companys market value. So it could almost certainly just borrow a little to fund another years growth, or else easily raise the cash by issuing a few shares.

As you can probably tell by now, were not too worried about G&E Herbal Biotechnologys cash burn. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. But its fair to say that its cash burn reduction was also very reassuring. After taking into account the various metrics mentioned in this report, were pretty comfortable with how the company is spending its cash, as it seems on track to meet its needs over the medium term. On another note, G&E Herbal Biotechnology has 4 warning signs (and 2 which dont sit too well with us) we think you should know about.

Of course G&E Herbal Biotechnology may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

PromotedWhen trading G&E Herbal Biotechnology or any other investment, use the platform considered by many to be the Professionals Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. *Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

Original post:
Companies Like G&E Herbal Biotechnology (GTSM:4911) Can Afford To Invest In Growth - Simply Wall St

Home News NTI convenes global experts on need for government oversight of biotechnology research

Shutterstock

The Nuclear Threat Initiative (NTI) convened a meeting of more than 40 experts worldwide to address the need for better oversight of biotechnology research.

Biotechnology research is essential for reducing pandemic threats and supporting global health. However, scientific advances in the life sciences, such as DNA synthesis and gene editing, are outpacing the ability of governments to provide effective oversight. Further, there is no international entity to uphold and oversee biosecurity norms, reduce biotechnology-related risks, and strengthen best practices for life science research oversight.

Without this oversight, the field is vulnerable to deliberate or accidental misuse of biotechnology. The COVID-19 pandemic has underscored the magnitude of these risks.

The attendees at this BTI meeting came from the United Nations, the biotech industry, philanthropies, academia, and non-governmental organizations. Addresses were delivered by Izumi Nakamitsu, under secretary general and high representative for disarmament affairs at the United Nations Office of Disarmament Affairs, and Arnaud Bernaert, head of shaping the future of health and healthcare at the World Economic Forum.

These global leaders discussed plans to establish an international entity for overseeing global biosecurity norms and best practices. The entity would have a systemic impact on the global biotechnology sector, bridging the gap between governance approaches developed by industry, civil society, and governments. They also discussed recent progress to create an international common mechanism for DNA synthesis screening.

Here is the original post:
NTI convenes global experts on need for government oversight of biotechnology research - Homeland Preparedness News